Upregulation of cytosolic phosphoenolpyruvate carboxykinase is a critical metabolic event in melanoma cells that repopulate tumors

Y Li, S Luo, R Ma, J Liu, P Xu, H Zhang, K Tang, J Ma… - Cancer research, 2015 - AACR
Y Li, S Luo, R Ma, J Liu, P Xu, H Zhang, K Tang, J Ma, Y Zhang, X Liang, Y Sun, T Ji…
Cancer research, 2015AACR
Although metabolic defects have been investigated extensively in differentiated tumor cells,
much less attention has been directed to the metabolic properties of stem-like cells that
repopulate tumors [tumor-repopulating cells (TRC)]. Here, we show that melanoma TRCs
cultured in three-dimensional soft fibrin gels reprogram glucose metabolism by hijacking the
cytosolic enzyme phosphoenolpyruvate carboxykinase (PCK1), a key player in
gluconeogenesis. Surprisingly, upregulated PCK1 in TRCs did not mediate …
Abstract
Although metabolic defects have been investigated extensively in differentiated tumor cells, much less attention has been directed to the metabolic properties of stem-like cells that repopulate tumors [tumor-repopulating cells (TRC)]. Here, we show that melanoma TRCs cultured in three-dimensional soft fibrin gels reprogram glucose metabolism by hijacking the cytosolic enzyme phosphoenolpyruvate carboxykinase (PCK1), a key player in gluconeogenesis. Surprisingly, upregulated PCK1 in TRCs did not mediate gluconeogenesis but promoted glucose side-branch metabolism, including in the serine and glycerol-3-phosphate pathways. Moreover, this retrograde glucose carbon flow strengthened rather than antagonized glycolysis and glucose consumption. Silencing PCK1 or inhibiting its enzymatic activity slowed the growth of TRCs in vitro and impeded tumorigenesis in vivo. Overall, our work unveiled metabolic features of TRCs in melanoma that have implications for targeting a unique aspect of this disease. Cancer Res; 75(7); 1191–6. ©2015 AACR.
AACR